Back to Journals » OncoTargets and Therapy » Volume 6
A miR-SNP of the XPO5 gene is associated with advanced non-small-cell lung cancer
Authors Ding C, Li C, Wang H, Li B, Guo Z
Received 14 May 2013
Accepted for publication 5 June 2013
Published 11 July 2013 Volume 2013:6 Pages 877—881
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Cuimin Ding,1 Cuiqiao Li,1 Hongjing Wang,1 Bin Li,1 Zhanjun Guo2
1Department of Respiratory Medicine, 2Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China
Objectives: MicroRNA (miRNA)-related single-nucleotide polymorphisms (SNPs) in miRNA processing machinery genes can affect cancer risk, treatment efficacy, and patient prognosis. A miR-SNP of rs11077 located in the 3' untranslated region (3' UTR) of the miRNA processing machinery gene XPO5 was examined in 112 advanced non-small-cell lung cancer (NSCLC) patients to evaluate its association with cancer outcome.
Materials and methods: The miR-SNP was genotyped with ligase detection reaction method. Survival curves were calculated using the Kaplan–Meier method, and multivariate survival analysis was performed using a Cox proportional hazards model.
Results: The AC genotype of rs11077, which carries C or A allele, was significantly associated with a better chemotherapy response (P = 0.001). In addition, rs11077 was independently associated with overall survival in advanced NSCLC patients through multivariate analysis (relative risk 0.457; 95% confidence interval: 0.251–0.831; P = 0.010).
Conclusion: rs11077 was associated with chemotherapy response and survival of advanced NSCLC patients. The analysis of miR-SNPs in miRNA processing machinery genes can help identify patient subgroups that are at high risk for poor disease outcomes.
Keywords: NSCLC, miR-SNP, survival, XPO5, rs11077, chemotherapy response
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.